By in silico analysis, Rab5A is found to be associated with poor prognosis in HR+ breast cancer [HR = 1.3 (1.01-1.6), P = 0.037] in multivariate analysis among tumors with Rab5A expression > 75% percentile[17]. Here, RAB5A is linked to breast cancer.